CARDIOVASCULAR HEALTH | PROACTIVE SCREENING

C

The Silent Threat in Your Aorta

A 10-minute ultrasound could be the most important screening you’ve never had.

Presented by the Bio Precision Editorial Team

April 2026

The Screening Most Men Never Get

If you’re a man over 60, there’s a strong chance your physician has checked your cholesterol, screened your prostate, and ordered a colonoscopy. But has anyone ever measured the diameter of your aorta?

Probably not. And that’s a problem.

Your aorta is the largest blood vessel in your body, a biological superhighway carrying oxygenated blood from the heart to every organ and tissue. Over decades of hemodynamic stress, the aortic wall can weaken and dilate, forming an aneurysm — a focal ballooning that typically produces zero symptoms until it ruptures. When it does rupture, mortality rates can exceed 80%, even with emergency surgery.

This is why aortic aneurysms have earned the sobering clinical nickname: the silent killer.

At Bio Precision Aging, we believe that where average is not the target, passive medicine should not be the default. A simple, painless abdominal ultrasound — a test that takes roughly 10 minutes — can detect an aneurysm years before it becomes life-threatening. The evidence supporting this screening in men is substantial, consistent, and published across some of the most respected medical journals in the world.

Let’s walk through what you need to know.

What Is an Aortic Aneurysm?

The normal abdominal aorta has an approximate diameter of 2.0 cm in most adult males, with minor variation based on age, height, and body surface area. An abdominal aortic aneurysm (AAA) is formally defined as a dilation of the abdominal aorta to a diameter of 3.0 cm or greater, or an increase of 50% above the normal vessel diameter.

Aneurysms can also occur in the thoracic aorta (ascending, arch, and descending segments), though abdominal aneurysms are the most common and the most extensively studied from a screening perspective. The pathogenesis is multifactorial — involving a combination of genetic susceptibility, atherosclerotic degeneration, chronic inflammation, and mechanical wall stress.

The critical clinical reality: most aneurysms are entirely asymptomatic. They grow silently over years, sometimes decades, until they either reach a size threshold where the risk of rupture or dissection accelerates — or they present catastrophically with no warning at all.

80–90%

of aortic aneurysms produce zero symptoms before rupture

Why Men Are at Significantly Higher Risk

The sex disparity in aortic aneurysm prevalence is one of the most consistent findings in cardiovascular epidemiology. Multiple large-scale population studies have confirmed that men are far more likely to develop aneurysms than women, particularly in the abdominal aorta.

The Data

Copenhagen General Population Study (2024): In a CT angiography study of 11,294 individuals (mean age 62), overall aneurysm prevalence was 4.0% in men versus 0.7% in women — a four-to-one ratio. Among men specifically, abdominal aortic aneurysms were the most common type (3.5%), followed by ascending aortic aneurysms (3.0%).

U.S. National Screening Database (2020): Among 9,457 screened individuals, male sex carried an odds ratio of 3.24 for AAA, independent of other risk factors. Among men ages 55–64 who smoked, prevalence reached 4.43%.

Serbian Pilot Screening Study (2024): Male sex was the strongest independent predictor, with an odds ratio of 8.04. Aneurysms were found in 8.2% of screened men compared to 1.3% of women.

Global Burden of Disease Analysis (2025): A comprehensive global analysis spanning 1990 to 2021 confirmed that males consistently carry a higher burden of aortic aneurysm-related mortality and disability-adjusted life years across all regions.

Key Risk Factors for Aortic Aneurysm

Risk Factor	Odds Ratio (Approx.)	Notes
Male Sex	3.2 – 8.0x	Strongest non-modifiable risk factor
Current Smoking	3.1 – 3.3x	Most potent modifiable risk factor
Former Smoking	1.9 – 2.1x	Risk persists after cessation
Family History of AAA	1.6 – 2.5x	First-degree relatives at elevated risk
Advancing Age	4.5x per decade	Prevalence climbs sharply after 60
Hypertension	2.0x (thoracic)	Especially linked to thoracic aneurysms
Hypercholesterolemia	2.4x (abdominal)	More strongly linked to AAA than thoracic
Overweight/Obesity	1.9x	Independent of other metabolic factors

Sources: Pham et al., Eur Heart J Cardiovasc Imaging, 2024; Koncar et al., Eur J Vasc Endovasc Surg, 2024; Defined et al., J Vasc Surg, 2020.

An important nuance: the risk factors differ by aortic segment. Hypertension is primarily associated with thoracicaortic aneurysms, while smoking and hypercholesterolemia are more strongly linked to abdominal aneurysms. This distinction matters for personalized risk assessment — a hypertensive patient with well-controlled lipids and no smoking history may carry a different segment-specific risk profile than a former smoker with high LDL.

The Evidence for Screening: What the Landmark Trials Show

The case for ultrasound-based AAA screening in older men is supported by some of the strongest randomized controlled trial evidence in preventive medicine.

The MASS Trial (Multicentre Aneurysm Screening Study)

The MASS trial is the gold-standard study in this field. Nearly 68,000 men aged 65–74 in the United Kingdom were randomized to either invitation to abdominal ultrasound screening or a control group with no screening.

At 10-year follow-up, the results were striking: AAA-related mortality was reduced by 48% in the screened group (relative risk reduction). The absolute risk of AAA death was 0.46% in the invited group versus 0.87% in the control group. Importantly, the mortality benefit did not diminish over time — the advantage was maintained and cost-effectiveness improved with longer follow-up.

Systematic Review and Meta-Analysis (2018)

A comprehensive meta-analysis pooling five major randomized trials (totaling more than 175,000 participants) confirmed the consistency of these findings across multiple countries and healthcare systems:

•       All-cause mortality: significantly reduced (HR 0.97, p = 0.002)

•       AAA-related mortality: reduced by 35% (HR 0.65, p = 0.008)

•       Emergency AAA repair: reduced by 36% (RR 0.64, p = 0.02)

•       Number needed to screen: 209–769 men to prevent one AAA-related death over 10 years

The meta-analysis also evaluated cost-effectiveness, finding a mean cost of approximately $16,854 per quality-adjusted life year (QALY) — well within the threshold typically considered acceptable by health economic standards.

48%

reduction in AAA-related mortality with one-time ultrasound screening (MASS trial, 10-year follow-up)

Current Screening Guidelines

U.S. Preventive Services Task Force (USPSTF) — 2019 Update

• B Recommendation: One-time ultrasound screening for AAA in men aged 65–75 who have ever smoked.

• C Recommendation: Selective screening for men aged 65–75 who have never smoked, based on individualized assessment.

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease

The 2022 joint guidelines from the American College of Cardiology and American Heart Association broadened the scope of screening recommendations significantly:

• All men and women aged 65 or older who have ever smoked or who have a first-degree relative with AAA should undergo abdominal ultrasound screening.

• For thoracic aortic disease, first-degree relatives of anyone diagnosed with aortic root or ascending aortic aneurysm or dissection should undergo screening imaging regardless of age.

• Genetic testing is recommended for individuals with syndromic features, family history of thoracic aortic disease, or early-onset disease.

• The surgical intervention threshold for ascending aortic aneurysms has been lowered to 5.0 cm (from 5.5 cm) at experienced, multidisciplinary aortic centers.

The Precision Aging Perspective

Standard guidelines set the screening floor at age 65 for men who have smoked. But if you are a man over 60 with hypertension, hyperlipidemia, a family history of cardiovascular disease, or elevated inflammatory biomarkers, the argument for earlier and more comprehensive aortic assessment is strong.

Beyond Abdominal: The Thoracic Aorta Deserves Attention Too

Most screening guidelines and public health programs have focused on abdominal aortic aneurysms, for good reason — the randomized trial evidence is concentrated there. However, thoracic aortic aneurysms (TAAs) and dissections represent a distinct and equally dangerous disease process that warrants awareness in any proactive health strategy.

Key considerations for the thoracic aorta:

• Different risk profile: Hypertension is the dominant modifiable risk factor for thoracic aneurysms, whereas smoking and dyslipidemia drive abdominal disease.

• Genetic component: Heritable thoracic aortic disease (including Marfan syndrome, Loeys-Dietz syndrome, bicuspid aortic valve-associated aortopathy, and familial non-syndromic thoracic aortic disease) accounts for a meaningful percentage of cases.

• Aging and vascular stiffening: Age-related loss of elastin content and increased collagen deposition reduce aortic distensibility, directly contributing to aneurysm formation and increased dissection risk.

• Emerging biomarker research: Studies in genomics and proteomics have identified candidate biomarkers (including pathways involving HIF-1 signaling and cellular senescence), though none have yet reached clinical utility for routine screening. Imaging remains the gold standard.

• For the precision health consumer, a transthoracic echocardiogram (TTE) can provide baseline aortic root and ascending aortic measurements. If your physician identifies dilation, follow-up with CT angiography or MRI provides more precise characterization.

What You Can Do: A Proactive Screening Roadmap

Step 1: Know Your Baseline

If you are a man over 60 (or a woman over 65 with a smoking history or family history of aneurysm), request an abdominal aortic ultrasound at your next primary care visit. This is a covered screening under Medicare for qualifying men aged 65–75 with a smoking history.

Step 2: Assess Your Thoracic Risk

If you have hypertension, a bicuspid aortic valve, a family history of aortic disease, or connective tissue features, discuss thoracic aortic imaging (echocardiogram, CT, or MRI) with your cardiologist.

Step 3: Manage the Modifiable

• Blood pressure: Aggressive optimization is critical. The 2022 ACC/AHA guidelines emphasize blood pressure control as the primary medical therapy for slowing aortic dilation.

• Smoking cessation: The single most impactful lifestyle change for reducing AAA risk and slowing growth.

• Lipid management: Statin therapy may provide additional benefit in slowing AAA progression, particularly in the presence of hypercholesterolemia.

• Exercise: Moderate aerobic exercise supports vascular health, but avoid extreme isometric straining if a known aneurysm exists. Discuss with your physician.

Step 4: Monitor if Found

If a small aneurysm (3.0–5.4 cm) is detected, surveillance ultrasound at regular intervals is the standard of care. Surgical intervention is generally recommended at 5.5 cm for men (5.0 cm for women) for abdominal aneurysms, or at growth rates exceeding 0.5 cm per year.

Recommended AAA Surveillance Intervals

Aortic Diameter	Surveillance Interval
3.0 – 3.9 cm	Every 3 years
4.0 – 4.9 cm	Every 12 months
5.0 – 5.4 cm	Every 6 months
≥5.5 cm (men) / ≥5.0 cm (women)	Surgical evaluation

Based on 2022 ACC/AHA Guidelines for the Diagnosis and Management of Aortic Disease.

How Aortic Aneurysms Are Treated

Understanding treatment options is an important part of the informed patient’s toolkit. While the goal of screening is early detection and surveillance, knowing what happens if intervention becomes necessary can reduce anxiety and support better decision-making with your medical team.

Medical Management: When the Aneurysm Is Small

The majority of screen-detected aneurysms are small (3.0–5.4 cm) and do not require immediate surgical intervention. Instead, these are managed with active surveillance and aggressive cardiovascular risk factor modification:

• Blood pressure control: The cornerstone of medical management. Beta-blockers and ACE inhibitors are commonly used to reduce hemodynamic stress on the aortic wall. The 2022 ACC/AHA guidelines emphasize blood pressure optimization as the primary medical therapy for slowing aortic dilation.

• Statin therapy: Growing evidence suggests statins may slow AAA progression independent of their lipid-lowering effects, likely through anti-inflammatory and plaque-stabilizing mechanisms.

• Smoking cessation: The single most impactful modifiable behavior. Continued smoking accelerates aneurysm growth rate and increases rupture risk. Cessation is non-negotiable.

• Regular imaging surveillance: Ultrasound at defined intervals (see surveillance table above) to track growth rate and determine if and when surgical thresholds are reached.

• For many patients with small aneurysms, this conservative approach can be maintained for years or even indefinitely if the aneurysm remains stable.

Surgical Repair: Two Evidence-Based Approaches

When an aneurysm reaches the threshold for repair — generally ≥5.5 cm in men and ≥5.0 cm in women for abdominal aneurysms, or with rapid growth exceeding 0.5 cm per year — two primary surgical options are available. Both are well-established, evidence-based interventions.

Comparing EVAR and Open Surgical Repair

	EVAR (Endovascular)	Open Surgical Repair
Approach	Minimally invasive; stent-graft delivered via femoral arteries using catheters and fluoroscopy	Transabdominal or retroperitoneal incision; aorta is cross-clamped and a synthetic graft is sewn in place
Anesthesia	General or regional	General endotracheal
Procedure Time	Typically 2–4 hours	Typically 3–6 hours
Hospital Stay	1–3 days	5–7 days (or longer)
Recovery	2–4 weeks to resume normal activity	6–12 weeks full recovery
30-Day Mortality (Elective)	~1–2%	~3–5%
Durability	Requires lifelong imaging surveillance for endoleaks	Generally more durable; fewer reinterventions
Anatomy Requirements	Requires suitable neck length (≥1.0–1.5 cm), neck diameter <3.2 cm, and accessible iliac arteries	No specific anatomic constraints; can address complex anatomy including juxtarenal disease
Best Candidates	Older patients, higher surgical risk, favorable anatomy	Younger patients, low surgical risk, complex or unsuitable EVAR anatomy

Sources: SVS Practice Guidelines (2018); ESVS 2024 Clinical Practice Guidelines; 2022 ACC/AHA Guidelines.

Endovascular Aneurysm Repair (EVAR)

EVAR has become the most commonly performed repair method for abdominal aortic aneurysms since its introduction in the early 1990s. The procedure involves threading a stent-graft — a fabric-covered metal scaffold — through small incisions in the femoral arteries in the groin, navigating it up to the aneurysm under fluoroscopic (X-ray) guidance, and deploying it within the aorta to create a new channel for blood flow that bypasses the weakened aneurysm wall.

The advantages of EVAR are significant: smaller incisions, shorter hospital stays, faster recovery, and lower perioperative mortality compared to open repair. For elective cases, 30-day mortality rates are typically in the range of 1–2%.

However, EVAR does come with an important trade-off: lifelong surveillance. Approximately 25% of EVAR patients develop endoleaks — situations where blood continues to flow into the aneurysm sac around the stent-graft. While many endoleaks (particularly Type II, from small branch arteries) are benign and resolve spontaneously, others (Type I and III) require reintervention. Current guidelines recommend CT angiography or duplex ultrasound at regular intervals following EVAR to monitor for these complications.

EVAR Follow-Up Schedule

Post-EVAR imaging is typically performed at 1 month, 6 months, and 12 months after the procedure, then annually thereafter. Some centers are now incorporating duplex ultrasound as a less invasive alternative to CT for long-term surveillance in patients with no endoleak at early follow-up.

Open Surgical Repair (OSR)

Open repair is the traditional and historically gold-standard surgical approach. The surgeon accesses the aorta through an abdominal incision, clamps the aorta above and below the aneurysm, opens the aneurysm sac, and sews a synthetic graft (typically made of Dacron or PTFE) directly into the healthy portions of the aorta. The aneurysm sac is then closed over the graft.

Open repair is a more invasive procedure with a longer recovery period, but it offers several distinct advantages: greater long-term durability, fewer reinterventions over time, and the ability to address complex anatomical situations that are not suitable for EVAR — including aneurysms that involve or extend close to the renal arteries (juxtarenal and pararenal aneurysms).

For elective cases, perioperative mortality at experienced centers is approximately 3–5%. The SVS guidelines recommend that elective open repair be limited to hospitals with documented mortality of 5% or less that perform at least 10 open aortic operations annually.

Thoracic and Thoracoabdominal Aneurysm Repair

Treatment of thoracic aortic aneurysms follows a parallel but distinct pathway. Thoracic endovascular aortic repair (TEVAR) has become increasingly utilized for descending thoracic aneurysms, while ascending aortic and aortic arch aneurysms typically require open surgical replacement — often involving cardiopulmonary bypass and, in some cases, circulatory arrest.

The 2022 ACC/AHA guidelines set the following surgical intervention thresholds for thoracic disease:

• Ascending aorta: ≥5.0 cm at experienced, multidisciplinary aortic centers (lowered from the previous 5.5 cm threshold); ≥4.5 cm in high-risk patients with connective tissue disorders.

• Descending thoracic: ≥6.0 cm, or ≥5.5 cm with risk factors for dissection.

• Rapid growth: Surgery recommended for confirmed growth of ≥0.3 cm/year across two consecutive years, or ≥0.5 cm in a single year.

• Heritable aortopathy: Lower thresholds may apply based on the specific genetic variant, family history of dissection, sex, and body size.

For patients with complex thoracoabdominal aneurysms, advanced endovascular techniques including fenestrated and branched grafts are an evolving field, with the 2024 ESVS guidelines providing the first comprehensive guidance on their use.

Emergency Repair: When Rupture Occurs

Ruptured aortic aneurysm remains a surgical emergency with extremely high mortality. Even with emergency surgery, in-hospital mortality following rupture can exceed 50%. Many patients do not survive to reach the hospital.

For ruptured AAA, current SVS guidelines recommend EVAR as the preferred treatment when the patient’s anatomy is suitable, as it is associated with lower perioperative mortality compared to emergency open repair. The guidelines also recommend a target door-to-intervention time of less than 90 minutes for ruptured aneurysms.

This is the most powerful argument for proactive screening: detecting and monitoring an aneurysm before rupture transforms a potential death sentence into a manageable, treatable condition.

Choosing the Right Approach: Shared Decision-Making

The decision between EVAR and open repair is not one-size-fits-all. It depends on a complex interplay of factors including the patient’s anatomy, age, comorbidities, life expectancy, and personal preferences. Both the ACC/AHA and ESVS guidelines emphasize the importance of shared decision-making between the patient and a multidisciplinary aortic team.

Key questions to discuss with your vascular surgeon:

1.     Is my anatomy suitable for EVAR, or is open repair recommended?

2.     What is this center’s volume and outcomes data for aortic repair?

3.     What does the long-term surveillance commitment look like after EVAR?

4.     Given my age, health status, and aneurysm characteristics, which approach offers the best balance of short-term safety and long-term durability?

5.     Are there emerging options (fenestrated grafts, branched devices) relevant to my specific anatomy?

Center Volume Matters

Both the SVS and ESVS guidelines emphasize that aortic repair outcomes are closely tied to institutional experience. The 2024 ESVS guidelines raised the minimum recommended caseload to 30 AAA repairs annually per center, with at least 15 each by open and endovascular methods. When choosing a provider, ask about their volume and outcomes data.

The Bottom Line

Aortic aneurysm screening is one of the most evidence-supported, cost-effective, and underutilized preventive tests available to men over 60. The data from multiple randomized controlled trials, meta-analyses, and population-based studies consistently shows that one ultrasound can reduce AAA-related death by nearly half.

Yet screening rates remain stubbornly low. Many primary care providers do not proactively offer aortic ultrasound outside of narrow guideline criteria. And for thoracic aortic disease, population-level screening protocols do not yet exist.

This is precisely the kind of gap that precision aging is designed to close. If you’re already tracking your lipids, HbA1c, inflammatory markers, and hormones, adding your aortic diameter to that panel is a natural and potentially life-saving extension of your approach.

Ask your doctor. Get the scan. Know your number.

Your Action Item

At your next annual physical or cardiology visit, request an abdominal aortic ultrasound. If you have hypertension or family history of aortic disease, ask about thoracic aortic imaging as well. This is a conversation worth starting.

Medical Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making decisions about screening, treatment, or changes to your health regimen.

References

1. Pham MHC, Sigvardsen PE, Fuchs A, et al. Aortic aneurysms in a general population cohort: prevalence and risk factors in men and women. Eur Heart J Cardiovasc Imaging. 2024;25(9):1235-1243.

2. Thompson SG, Ashton HA, Gao L, Scott RAP; Multicentre Aneurysm Screening Study Group. Screening men for abdominal aortic aneurysm: 10-year mortality and cost effectiveness results from the randomised MASS trial. BMJ. 2009;338:b2307.

3. Defined DB et al. Evaluating the prevalence of abdominal aortic aneurysms in the United States through a national screening database. J Vasc Surg. 2020;72(1):75-82.

4. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for abdominal aortic aneurysm: USPSTF recommendation statement. JAMA. 2019;322(22):2211-2218.

5. Koncar IB, Jovanovic A, Kostic O, et al. Screening men and women above the age of 50 years for abdominal aortic aneurysm: a pilot study. Eur J Vasc Endovasc Surg. 2024;68(1):10-15.

6. Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-analysis of population-based screening for abdominal aortic aneurysm. J Vasc Surg. 2010;52(4):1103-1108.

7. Isselbacher EM, Preventza O, Hamilton Black J III, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146(24):e334-e482.

8. Global Burden of Disease 2021 Collaborators. Global, regional, and national burden of aortic aneurysm and its attributable risk factors from 1990 to 2021. Published 2025.

9. Li J, Pan C, Lu J, et al. The global and regional prevalence of abdominal aortic aneurysms: a systematic review and modeling analysis. Ann Surg. 2023;277(6):912-919.

10. Svensjö S, Björck M, Wanhainen A. Screening for abdominal aortic aneurysm in 65-year-old men remains cost-effective with contemporary epidemiology and management. Eur J Vasc Endovasc Surg. 2014;47(4):357-365.

11. Zhang Y, Li H, Wang K, et al. Bioinformatics analysis of aging-related genes in thoracic aortic aneurysm and dissection. Front Cardiovasc Med. 2023;10:1137985.

12. Czerny M, Grabenwöger M, Berger T, et al. EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Ann Thorac Surg. 2024;118(1):5-115.

13. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.e2.

14. Wanhainen A, Van Herzeele I, Gonçalves FB, et al. Editor’s Choice — ESVS 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192-331.

15. Bailey IB, Shaydakov ME, Shaw PM. Abdominal Aorta Aneurysm Repair. StatPearls [Internet]. Updated September 4, 2023.

16. Kim HO, Yoo JH. Endovascular Aneurysm Repair for Abdominal Aortic Aneurysm: A Comprehensive Review. Korean J Radiol. 2019;20(8):1247-1261.

ABOUT BIO PRECISION AGING

Bio Precision Aging is an evidence-based longevity and health optimization platform for executives and professionals who want to go beyond standard-of-care medicine. Our content is grounded in peer-reviewed research and reviewed by our clinical advisory team. Visit us at bioprecisionaging.com.